Bristol-Myers Squibb enters agreement to acquire Promedior, Inc.

Providing exclusive right to novel PRM-151 in development for fibrotic diseases

03-Sep-2015 - Bristol-Myers Squibb Company and Promedior, Inc. announced that the companies have entered into an agreement that grants Bristol-Myers Squibb an exclusive right to acquire Promedior and gain worldwide rights to its lead asset PRM-151, a recombinant form of human pentraxin-2 protein in Phase 2 ...

S*BIO’s Novel JAK2 Inhibitor Pacritinib (SB1518) Effectively Reduces Splenomegaly in Myelofibrosis (MF) Patients

15-Dec-2011 - S*BIO Pte Ltd announced that results from a Phase 2 study demonstrated that its JAK2 inhibitor pacritinib (SB1518) effectively reduced splenomegaly in myelofibrosis (MF) patients, with minimal impact on existing cytopenias providing an important therapeutic niche in the treatment of MF. Results ...

S*BIO to Initiate Global Phase 3 Clinical Trials of its Novel JAK2 Inhibitor Pacritinib for Treatment of Myelofibrosis (MF)

27-Oct-2011 - S*BIO Pte Ltd announced plans to initiate a global Phase 3 clinical program of its novel JAK2 inhibitor pacritinib (SB1518), in the first half of 2012 to further demonstrate its activity and tolerability for the treatment of myelofibrosis (MF). The company is actively exploring partnering ...

Novartis JAK inhibitor INC424 shows significant clinical benefit for myelofibrosis patients in two Phase III studies

09-Jun-2011 - Novartis announced results from two pivotal Phase III studies demonstrating the effects of investigational Janus kinase (JAK) inhibitor INC424 (ruxolitinib) in treating patients with myelofibrosis, a blood cancer with limited treatment options. These data are being presented at the 47th American ...

Additional Data from Multiple Phase 1 and 2 Studies of S*BIO’s Novel JAK2 Inhibitor SB1518 Demonstrate Safety and Efficacy for Treatment of Symptomatic Myelofibrosis

SB1518 Alleviates MF-Associated Splenomegaly and Shows No Myelosuppression and No Exacerbation of Cytopenias

07-Jun-2011 - S*BIO Pte Ltd announced that additional data from multiple Phase 1 and 2 clinical studies of its novel JAK2 inhibitor SB1518 further confirmed safety and efficacy for the treatment of patients with symptomatic myelofibrosis (MF) and enlarged spleens. In the studies, SB1518 alleviated ...

Second Phase III study of Novartis JAK inhibitor INC424 meets primary endpoint in patients with myelofibrosis

COMFORT-II data show INC424 provides marked clinical improvement in patients with myelofibrosis, measured by reduction in spleen size at 48 weeks compared to best available therapy

17-Mar-2011 - Novartis announced that a pivotal Phase III trial of the investigational Janus kinase (JAK) inhibitor INC424 (ruxolitinib) has met its primary endpoint of significantly reducing spleen size in patients with myelofibrosis (MF). INC424 is a potent, selective inhibitor of the JAK1 and JAK2 tyrosine ...

S*BIO’s JAK2 Inhibitor SB1518 Granted Orphan Drug Designation by European Commission for the Treatment of Myelofibrosis

20-Oct-2010 - S*BIO Pte Ltd announced that the European Commission (EC) has granted orphan drug designation to SB1518, its potent and orally active JAK2 inhibitor for the treatment of primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and postessential thrombocythemia myelofibrosis ...

YM BioSciences granted Orphan Drug Designation for CYT387

JAK1/2 inhibitor currently in Phase II clinical study in myelofibrosis

12-Aug-2010 - YM BioSciences Inc. announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the Company's highly-selective JAK1/2 inhibitor, CYT387, for the treatment of myelofibrosis, a chronic debilitating unmet medical ...

Sanofi-aventis to acquire TargeGen Inc.

Development of oral potent oncology medicines for the treatment of hematological malignancies

02-Jul-2010 - Sanofi-aventis announced that it has signed an agreement for the acquisition of TargeGen Inc., a privately held US biopharmaceutical company developing small molecule kinase inhibitors for the treatment of certain forms of leukemia, lymphoma and other hematological malignancies and blood ...

S*Bio presents positive safety and tolerability results for its oral JAK2 inhibitor SB1518 for the treatment of myelofibrosis

15-Jun-2010 - S*BIO Pte Ltd announced the presentation of positive safety, tolerability and pharmacokinetic/pharmacodynamic (PK/PD) results for its novel oral JAK2 inhibitor, SB1518, at the 15th Congress of the European Hematology Association (EHA), June 10-13, in Barcelona, Spain. Data was presented on the ...